Liquid Biopsy — Early Cancer Detection Before Conventional Diagnosis

The claim is partially supported and fragmenting. Blood-based liquid biopsy can detect cancer signals before conventional diagnosis in a demonstrable fraction of cases — the Galleri test's performance data establishes this for multiple cancer types. The detection is reliable in a technical sense: specificity is high (98.4%) and sensitivity, while lower than desired, is non-trivial across cancer types. For the claim as stated, this constitutes partial confirmation: early detection before conventional diagnosis is achievable in some cases. The claim fragments on the central unresolved question: whether that earlier detection reduces cancer mortality, or whether it produces stage shift and lead-time effects without a genuine survival benefit (IN-004). Sensitivity is markedly lower for early-stage disease (approximately 24% at Stage I) — precisely the regime in which the claim's value would be greatest — and the NHS-Galleri trial (INST-003), the first to test the claim against a mortality endpoint directly, has not yet reported. The pressure state is FRAGMENTING: the technology works as a detection instrument, but whether detection translates into the clinical benefit the claim asserts remains genuinely open (AT-001).

The NHS-Galleri trial's full results (INST-006) sustain rather than resolve the FRAGMENTING state identified at AS-001. The trial delivers exactly the kind of evidence the record's attractor (AT-001) was built to await, and the result is genuinely mixed rather than confirmatory or disconfirming: a real, substantial reduction in late-stage diagnoses coexists with a missed primary endpoint, an unexpected rise in Stage III diagnoses, and no mortality data. This is not a null result — the four-fold detection-rate increase and Stage IV reduction are real signals — but it does not resolve the central contested question (OQ-001): whether earlier detection translates into reduced mortality, or whether it is partially absorbed by stage migration and lead-time effects that RM-001/AT-001 already anticipated. Verification stage advances to VS-04 (Replication): a population-scale randomised trial has now run and reported, the most rigorous test design available short of mortality follow-up itself. The record should be re-entered when GRAIL's extended follow-up data (6–12 months from this release) becomes available, since that data — not this release — is positioned to address OQ-001 directly.